BACKGROUND Renal cell carcinoma (RCC) is the most common malignant kidney tumour in adults. The vascular endothelial growth factor (VEGF) is thought to play a major role in tumour angiogenesis. Ki-67 has been shown to be of prognostic significance in RCCs. With the availability of more effective molecular targeted therapy for specific renal neoplasms, immunohistochemical (IHC) techniques play an important role in diagnosis and prognostication of RCCs. This study aims to evaluate the expression pattern of VEGF and Ki-67 in histologically diagnosed cases of RCC and correlate and compare VEGF and Ki-67 expression with grade and stage of RCC and also compare VEGF expression and Ki-67 index if any. MATERIALS AND METHODS This was a cross-sectional observational study. A total of 50 patients of RCC undergoing total and partial nephrectomy were included in this study. The expressions of Ki-67 and VEGF were studied by IHC. Statistical Analysis was performed with the help of Epi Info (TM) 7.2.2.2. p value of ≤0.05 was considered statistically significant. RESULTS Out of 50 tumours, 21 tumours were VEGF Grade 1, 19 tumours were VEGF Grade 2. 27 tumours had Ki67 labelling index≥15%. There was significant association of VEGF grades and Ki-67 labelling index with stage and histological grade. Ki-67 labelling index showed significantly increasing trend with the increase in VEGF grades of the tumours. CONCLUSION This study suggests that there are significant differences in VEGF expression and Ki-67 labelling index with tumour stage and grade and other prognostic parameters of RCC. These biomarkers can be considered as a prognostic parameters and critical evaluator of targeted chemotherapy in RCC. A wider evaluation involving large number of cases with proper follow up facility is needed to validate these findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.